CalciMedica, Inc. (NASDAQ:CALC) Insider Eric W. Roberts Purchases 53,333 Shares of Stock

CalciMedica, Inc. (NASDAQ:CALC) insider Eric W. Roberts acquired 53,333 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, for a total transaction of $199,998.75. Following the acquisition, the insider now owns 164,706 shares in the company, valued at approximately $617,647.50. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CalciMedica Trading Down 5.1 %

CalciMedica stock opened at $3.51 on Friday. CalciMedica, Inc. has a 1 year low of $2.14 and a 1 year high of $8.38. The company has a market cap of $37.73 million, a PE ratio of -2.51 and a beta of 1.30. The company’s 50-day moving average is $4.25 and its two-hundred day moving average is $4.63.

CalciMedica (NASDAQ:CALC) last released its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. Research analysts forecast that CalciMedica, Inc. will post -2.21 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CALC. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of CalciMedica in a report on Tuesday, August 13th. Oppenheimer increased their price objective on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, July 10th.

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc lifted its position in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the period. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.